KOMORBID HOLATLARI BO’LGAN BEMORLARDA YURAK KORONAR KASALLIKLARNING KLINIK VA INSTRUMENTAL XUSUSIYATLARI
##article.subject##:
Arterial gipertenziya, qandli diabet, yurak ishemik kasalligi, EKG, miokard infarkti, yurak-qon tomir kasalliklari##article.abstract##
Arterial gipertenziya va 2-toifa diabet tez-tez uchraydigan kasalliklardir. Qandli diabet bilan og'rigan bemorlarda arterial gipertenziya diabetsiz bemorlarga qaraganda ikki baravar tez-tez uchraydi.
Tadqiqot maqsadi: II turdagi qandli diabet bilan birgalikda arterial gipertenziya bilan og'rigan bemorlarda koronar arteriya kasalligining klinik va instrumental xususiyatlarini ochib berish.
Tadqiqot materiallari va usullari: Bemorlarni klinik ko'rikdan o'tkazishga alohida e'tibor qaratildi, unda shikoyatlar to'plash, anamnez va fizik tekshiruvlar o'tkazildi. Infarktdan keyingi kardioskleroz diagnostikasi anamnestik ma'lumotlar, EKG ma'lumotlari, Xolter monitoringi va exokardiografiya asosida amalga oshiriladi. Instrumental tadqiqotga EKG, exokardiyografiya, uyqu arteriyalarning intima-media kompleksining qalinligini aniqlash, ko'krak qafasi organlarining rentgenogrammasi kiradi. Ishemiya Xolter-EKG yoki stress testlarini tekshirish uchun SYuY bilan kasallangan odamlar uchun.
Tadqiqot natijalari: biz tomonidan o'rganilgan ko'rsatkichlar 2-toifa diabet ko'rinishidagi birgalikda patologiyasi bo'lgan bemorlar asosiy kasallikning kechishini og'irlashtirishini tasdiqladi. QD ning birgalikdagi kursida EKG monitoringi ko'rsatkichlari ST segment depressiyasini ko'rsatdi, bu koronar ateroskleroz xavfini asoslash, 2-toifa diabet bilan og'rigan bemorlarda kasallikning atipik kechishida surunkali koronar arteriya kasalligining yashirin shakllarini aniqlash imkonini beradi.
Библиографические ссылки
Khan S.S., Quaggin S.E. Therapies on the horizon for diabetic kidney disease. Curr Diab Rep. 2015;15:111.
Leung A.A., Daskalopoulou S.S., Dasgupta K. Hypertension Canada's 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–576.
Lewis D.R., Petersen L.K., York A.W. Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. Cardiovasc Res. 2016;109:283–293.
Yonchuk J.G., Foley J.P., Bolognese B.J. Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2h-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017;363:114–125.
Sharma A., Rizky L., Stefanovic N. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. Cardiovasc Diabetol. 2017;16:33.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2017.11.006.
Zhuge F., Ni Y., Nagashimada M. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes. 2016;65:2966–2979.
Ташкенбаева Э. Н., Насырова З. А., Мирзаев Р. З. СТРАТИФИКАЦИЯ ХРОНИЧЕСКОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА В ЗАВИСИМОСТИ ОТ МЕТОДОВ ДИАГНОСТИКИ И ПУТИ ИХ ЛЕЧЕНИЯ //Журнал кардиореспираторных исследований. – 2020. – Т. 1. – №. 3.
Элламонов С. Н. и др. ФАКТОРЫ ПРОГРЕССИРОВАНИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У БОЛЬНЫХ В КОМОРБИДНОСТИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2.
